The global urinalysis market size is expected to reach USD 6.85 billion by 2030, expanding at a CAGR of 7.83% from 2025 to 2030, according to a new report by Grand View Research, Inc. Increasing incidence of UTI worldwide contributes to market growth. According to a study published by SHEA journal, in 2021, approximately 60% to 70% of urinalyses were being performed in patients without symptoms referable to the Gastrointestinal Tract (GU).
Increasing geriatric population and the subsequent increase in age related diseases in developed and developing regions will positively influence urinalysis market growth. According to the World Health Organization (WHO), the geriatric population increased from 1 billion in 2020 to 1.4 billion in 2021. The early diagnosis and management of chronic diseases in geriatric population is responsible for the increasing prescription rate for tests such as bilirubin, ketones, glucose, and creatinine. These tests are performed by urinalysis; hence, it is anticipated to drive market growth.
Moreover, for patients undergoing transplant surgeries including kidney and liver, transplant procedures is often recommended to undergo preoperative urinalysis to avoid urinary tract infections (UTIs). According to United Network for Organ Sharing data, around 24,669 kidney transplants, 9,236 liver transplants, and 3,817 heart transplants were performed in the U.S. in 2021. Thus, an increasing number of transplant surgeries is expected to fuel market growth.
Companies are taking initiatives such as collaboration and strategic partnerships for the development and marketing of technologically advanced urinalysis products. For instance, in October 2021, Sysmex entered into collaboration with Inpeco for the development of an automated urinalysis workflow solution of the highest level. This product was developed with a help of UN-Series of Sysmex's and FlexLab TM track of Inpeco’s urinalysis solutions. It is the only fully open automation system that helps laboratories optimize their workflow support and provide premium patient care.
Request a free sample copy or view report summary: Urinalysis Market Report
The consumables segment held the dominant revenue share of 78.56% in terms of revenue in 2024. This dominance can be attributed to the increasing demand and frequent purchases of reagents and dipsticks by clinical and hospital laboratories.
The urinary tract infection screening segment dominated the market and accounted for a revenue share of 24.07% in 2024, due to the rising incidence of UTIs worldwide.
The clinical laboratories segment accounted for the highest revenue share of around 45.88% in 2024. This can be attributed to their easy accessibility to patients and the availability of advanced products in these laboratories.
North America urinalysis market dominated the market and accounted for the largest revenue share of 37.9% in 2024.
Grand View Research has segmented the global urinalysis market on the basis of product, application, end-use, and region:
Urinalysis Product Outlook (Revenue, USD Billion, 2018 - 2030)
Instruments
Biochemical Urine Analyzer
Automated Biochemical Analyzers
Semi-automated Urine Sediment Analyzers
Automated Urine Sediment Analyzers
Microscopic Urine Analyzers
Flowcytometric Urine Analyzers
Consumables
Dipsticks
Reagents
Disposables
Urinalysis Application Outlook (Revenue, USD Billion, 2018 - 2030)
UTI Screening
Diabetes
Kidney Disease
Hypertension
Liver Disease
Others
Urinalysis End Use Outlook (Revenue, USD Billion, 2018 - 2030)
Hospitals
Clinical Laboratories
Home Care
Research and Academics
Others
Urinalysis Regional Outlook (Revenue, USD Billion, 2018 - 2030)
North America
U.S.
Canada
Mexico
Europe
UK
Germany
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
Japan
China
India
South Korea
Australia
Thailand
Latin America
Brazil
Argentina
Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait
List of Key Players in the Urinalysis Market
Abbott
Sysmex Corporation
Siemens Healthineers AG
ACON Laboratories, Inc.
ARKRAY Inc.
Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
F. Hoffmann-La Roche Ltd.
Quidel Corporation
Bio-Rad Laboratories, Inc.
"The quality of research they have done for us has been excellent..."